Analyst Price Target is $9.00
▲ +426.32% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Bio-Path in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 426.32% upside from the last price of $1.71.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Bio-Path. This Buy consensus rating has held steady for over two years.
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.